Key facts
- This page summarizes Kevin Tan's Form 4 filing for SELECTA BIOSCIENCES INC (RNAC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2022, 15:36.
Kevin Tan - 03 Jan 2022 Form 4 Insider Report for SELECTA BIOSCIENCES INC (RNAC)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RNAC
- Reported as of
- 03 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 15:36:06 UTC
- Prior SEC filing
- 06 Dec 2021
- Next SEC filing
- 11 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Bartholomae, Attorney-in-Fact for Kevin Tan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Tan filed Form 4 for SELECTA BIOSCIENCES INC (RNAC) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 06 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SELB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +72,000
- Change %
- +1440%
- Price
- $0.000000
- Shares after
- 77,000
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SELB
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +340,000
- Change %
- Price
- $0.000000
- Shares after
- 340,000
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 340,000
- Exercise price
- $3.31
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026.
Footnote F2
This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.